SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 8)*
Inamed Corporation
(Name of Issuer)
Common Stock, Par Value $.01
(Title of Class of Securities)
453235103
(CUSIP Number)
Arthur Goetchius
300 Park Avenue, 21st Fl., New York, NY 10022 (212) 755-9395
(Name, address and telephone number of person
authorized to receive notices and communications)
August 15, 1995
(Date of event which requires filing of this statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box [ ].
Check the following box if a fee is being paid with the statement [ ].
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent
of the class of securities described in Item 1; and (2) has filed no
amendment subsequent thereto reporting beneficial ownership of five percent
or less of such class.) (See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom
copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
<PAGE>
13D
CUSIP No. 453235103
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
EGS Associates, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
65,408
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
65,408
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
65,408
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
0.87%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
EGS Partners, L.L.C.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
98,183
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
98,183
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
98,183
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
1.30%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IA
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Bev Partners, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
52,112
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
52,112
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
52,112
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
0.69%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
The Pharmaceutical/Medical Technology Fund, L.P.
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
WC
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
108,797
OWNED BY ___________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
108,797
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
108,797
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
1.45%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
PN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
William Ehrman
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
PF AF
____________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
6,400
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
330,800
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
6,400
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
330,800
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
337,200
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
4.46%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Frederic Greenberg
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF PF
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
-0-
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
342,000
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
-0-
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
342,000
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
342,000
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
4.53%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Frederick Ketcher
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF PF
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
9,500
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
325,000
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
9,500
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
325,000
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
334,500
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
4.43%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
13D
CUSIP No. 453235103
_____________________________________________________________________________
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO.
OF ABOVE PERSON
Jonas Gerstl
_____________________________________________________________________________
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **
(a) [ ]
(b) [X]
_____________________________________________________________________________
(3) SEC USE ONLY
_____________________________________________________________________________
(4) SOURCE OF FUNDS **
AF PF
_____________________________________________________________________________
(5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
_____________________________________________________________________________
(6) CITIZENSHIP OR PLACE OF ORGANIZATION
United States
_____________________________________________________________________________
NUMBER OF (7) SOLE VOTING POWER
2,000
SHARES ______________________________________________________________
BENEFICIALLY (8) SHARED VOTING POWER
324,500
OWNED BY ______________________________________________________________
EACH (9) SOLE DISPOSITIVE POWER
2,000
REPORTING ______________________________________________________________
PERSON WITH (10) SHARED DISPOSITIVE POWER
324,500
_____________________________________________________________________________
(11) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON
326,500
_____________________________________________________________________________
(12) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES ** [ ]
_____________________________________________________________________________
(13) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (11)
4.32%
_____________________________________________________________________________
(14) TYPE OF REPORTING PERSON **
IN
_____________________________________________________________________________
** SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
The Schedule 13D, initially filed on April 6, 1992, is hereby amended
by this Amendment No. 8 to the Schedule 13D as follows:
ITEM 1. SECURITY AND ISSUER.
No Change.
ITEM 2. IDENTITY AND BACKGROUND.
No Change.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
No Change.
ITEM 4. PURPOSE OF THE TRANSACTION.
No Change.
Item 5 is hereby amended and restated in its entirety as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) The approximate aggregate percentage of shares of Common Stock reported
beneficially owned by each person herein is based on 7,552,739 shares
outstanding, which is the total number of shares of Common Stock outstanding
as of June 30, 1995, as reflected in the company's quarterly report on Form
10-Q filed with the Securities and Exchange Commission (the "Commission")
for the fiscal quarter ended June 30, 1995 (which is the most recent Form
10-Q on file).
As of the close of business on August 15, 1995:
(i) EGS Associates owns beneficially 65,408 shares of Common Stock,
constituting less than 1% of the shares outstanding.
(ii) EGS Partners owns directly no shares of Common Stock. By reason of
the provisions of Rule 13D-3 of the Securities Exchange Act of 1934, as
amended (the "Act"), EGS Partners may be deemed to own beneficially 80,242
shares (constituting approximately 1.07% of the shares outstanding),
purchased for discretionary accounts managed by it, other than EGS Overseas,
and 17,941 shares of Common Stock purchased for EGS Overseas (less than 1%
of the shares outstanding), which, when aggregated, total 98,183 shares of
Common Stock, constituting approximately 1.30% of the shares outstanding.
(iii) Bev Partners owns beneficially 52,112 shares of Common Stock,
constituting less than 1% of the shares outstanding.
(iv) Pharm Fund owns 108,797 shares of Common Stock, constituting
approximately 1.45% of the shares outstanding.
(v) Mr. Ehrman owns directly, and beneficially through ownership by
members of his immediate family, 12,700 shares of Common Stock, constituting
less than 1% of the shares outstanding.
(vi) Mr. Greenberg owns beneficially through ownership by members of
his immediate family, 17,500 shares of Common Stock, constituting less than
1% of the shares outstanding.
(vii) Mr. Ketcher owns directly, and beneficially through ownership by
members of his immediate family, 10,000 shares of Common Stock.
(viii) Mr. Gerstl owns directly 2,000 shares of Common Stock.
By reason of the provisions of Rule 13D-3 of the Act, each of the General
Partners may be deemed to own the 65,408 shares beneficially owned by EGS
Associates, the 98,183 shares beneficially owned by EGS Partners, the 52,112
shares beneficially owned by Bev Partners and the 108,797 shares beneficially
owned by Pharm Fund. When the shares beneficially owned by EGS Associates,
EGS Partners, Bev Partners, and Pharm Fund are aggregated, they total
324,500 shares of Common Stock, constituting approximately 4.30% of the shares
outstanding.
(ix) In the aggregate, the Reporting Persons beneficially own a total of
366,700 shares of Common Stock, constituting approximately 4.86% of the
shares outstanding.
(b) (i) Each of EGS Associates, EGS Partners (with respect to shares of
EGS Overseas and other discretionary accounts), Bev Partners and Pharm Fund
has the power to vote and to dispose of the shares of Common Stock
beneficially owned by it, which power may be exercised by the General
Partners. Each of EGS Overseas and the discretionary accounts is a party to
an investment management agreement with EGS Partners pursuant to which EGS
Partners has investment authority with respect to securities held in such
account.
(ii) Each General Partner has the sole power to vote and dispose of the
shares owned directly by him. Messrs. Ehrman and Greenberg have shared
power to vote and dispose of shares owned by members of their immediate
family. Mr. Gerstl has shared power to vote and dispose of shares owned
jointly with members of his immediate family.
(c) The trading dates, number of shares of Common Stock purchased or sold
and price per share for all transactions in the Common Stock from the 60th
day prior to August 15, 1995 until August 15, 1995 by EGS Associates, EGS
Partners (excluding EGS Overseas), EGS Overseas, Pharm Fund, Bev Partners,
Mr. Ehrman, Mr. Greenberg, Mr. Gerstl and Mr. Ketcher are set forth in
Schedules A, B, C, D, E, F, G, H and I, respectively, and were all effected
in the over-the-counter market or on the Pacific Stock Exchange.
(d) No person other than each respective record owner referred to herein
of shares of Common Stock is known to have the right to receive or the power
to direct the receipt of dividends from or the proceeds of sale of such
shares of Common Stock.
(e) The Reporting Persons ceased to be the beneficial owners of more than
5% of the Common Stock on August 15, 1995.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER.
No Change.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
No Change.
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is
true, complete and correct.
DATED: August 16, 1995
/s/ Frederic Greenberg
Frederic Greenberg, as Attorney-In-Fact for William Ehrman, individually
and as general partner of each of EGS PARTNERS, L.L.C., EGS ASSOCIATES, L.P.,
BEV PARTNERS, L.P. and THE PHARMACEUTICAL/MEDICAL TECHNOLOGY FUND, L.P.
/s/ Frederic Greenberg
Frederic Greenberg, individually and as general partner of each of EGS
PARTNERS, L.L.C., EGS ASSOCIATES, L.P., BEV PARTNERS, L.P. and THE
PHARMACEUTICAL/MEDICAL TECHNOLOGY FUND, L.P.
/s/ Frederick Ketcher
Frederick Ketcher, individually and as general partner of each of EGS
PARTNERS, L.L.C., EGS ASSOCIATES, L.P., BEV PARTNERS, L.P. and THE
PHARMACEUTICAL/MEDICAL TECHNOLOGY FUND, L.P.
/s/ Jonas Gerstl
Jonas Gerstl, individually and as general partner of each of EGS PARTNERS,
L.L.C., EGS ASSOCIATES, L.P., BEV PARTNERS, L.P. and THE PHARMACEUTICAL/
MEDICAL TECHNOLOGY FUND, L.P.
<PAGE>
Schedule A
EGS Associates, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
8/1/95 (7,387) $8.66
8/4/95 (9,780) $9.13
8/4/95 (9,030) $8.86
8/8/95 (30,000) $10.88
8/10/95 (2,002) $11.63
8/10/95 (3,003) $11.62
8/15/95 (6,500) $13.69
<PAGE>
Schedule B
EGS Partners, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
8/1/95 (23,912) $8.66
8/3/95 (6,500) $8.57
8/4/95 (5,100) $9.13
8/4/95 (4,708) $8.86
8/8/95 (40,000) $10.88
8/10/95 (2,154) $11.63
8/10/95 (3,231) $11.62
8/15/95 (12,500) $13.69
<PAGE>
Schedule C
EGS Overseas Fund, Ltd.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
8/1/95 (1,793) $8.66
8/3/95 (5,000) $8.57
8/4/95 (2,370) $9.13
8/4/95 (2,188) $8.86
8/8/95 (20,000) $10.88
8/10/95 (639) $11.63
8/10/95 (958) $11.62
8/15/95 (5,000) $13.69
<PAGE>
Schedule D
The Pharmaceutical/Medical Technology Fund, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
8/1/95 (4,740) $8.66
8/4/95 (6,300) $9.13
8/4/95 (5,817) $8.86
8/8/95 (45,000) $10.88
8/10/95 (3,586) $11.63
8/10/95 (5,380) $11.62
8/15/95 (10,000) $13.68
8/15/95 (10,000) $13.69
<PAGE>
Schedule E
Bev Partners, L.P.
Transactions in the Common Stock
Price Per Share
Date of Number of (including
Transaction Shares Purchased/(Sold) Commissions, if any)
8/1/95 (4,868) $8.66
8/4/95 (6,450) $9.13
8/4/95 (5,957) $8.86
8/8/95 (40,000) $10.88
8/10/95 (1,619) $11.63
8/10/95 (2,428) $11.62
8/15/95 (6,000) $13.69
<PAGE>
Schedule F
William Ehrman
Transactions in the Common Stock
Price Per Share
Date of Number of (excluding
Transaction Shares Purchased/(Sold) Commissions, if any)
6/9/95 1,000** $3.50
6/19/95 1,000** $3.38
6/23/95 1,000 $3.38
8/7/95 (14,000) $9.61
8/7/95 (21,000)* $9.65
8/7/95 (5,000)* $9.61
8/8/95 (2,600)** $9.88
8/8/95 (2,000)** $9.75
8/8/95 (8,000)** $9.31
8/15/95 (4,000)* $12.75
_________________________________
* Shares held in an account for the benefit of Mr. Ehrman's spouse.
** Shares held in an account for the benefit of Mr. Ehrman's daughter.
<PAGE>
Schedule G
Frederic Greenberg
Transactions in the Common Stock
Price Per Share
Date of Number of (excluding
Transaction Shares Purchased/(Sold) Commissions, if any)
8/8/95 (6,500) $9.88
8/8/95 (10,000) $9.31
<PAGE>
Schedule H
Jonas Gerstl
Transactions in the Common Stock
Price Per Share
Date of Number of (excluding
Transaction Shares Purchased/(Sold) Commissions, if any)
8/14/95 (3,000) $10.75
<PAGE>
Schedule I
Frederick Ketcher
Transactions in the Common Stock
Price Per Share
Date of Number of (excluding
Transaction Shares Purchased/(Sold) Commissions, if any)
8/8/95 (800)* $9.88
8/9/95 (9,000) $11.75
_________________________________
* Shares held in an account for the benefit of Mr. Ketcher's son.
